close
close

To observe high -growth technology stocks in May 2025

The global markets have experienced a positive shift, since the US shares on the back of a temporary suspension of tariffs between the USA and China led to the most important growth in the important indices such as the Nasdaq Composite and S&P 500. This optimistic environment, which is connected to the cooling of the inflation rate in April, creates a fascinating economic emergency.

name

Sales growth

Profit growth

Growth assessment

Shanghai Huace Navigation Technology

24.40%

23.42%

★★★★earch

Kebni

21.51%

66.96%

★★★★earch

Yubico

20.18%

30.36%

★★★★earch

Pharma Mar

25.21%

43.09%

★★★★earch

Ewellltd

24.95%

24.42%

★★★★earch

Elicera therapeutics

75.80%

107.14%

★★★★earch

CD project

33.48%

37.39%

★★★★earch

Elliptical laboratories

36.34%

79.05%

★★★★earch

Arabic contract services

20.34%

32.01%

★★★★earch

Jntc

34.26%

86.00%

★★★★earch

Click here to display the full list of 750 shares from our Global High Growth Tech and Ai Stocks screener.

Let us get out of the screen in some first -class options.

Simply wall st -growth level: ★★★★★ ☆

Overview: Cutia Therapeutics is an investment holding company that focuses on research, development, manufacture and marketing of scalp diseases and skin care products in the People's Republic of China and Hong Kong with a market capitalization of $ 2.64 billion.

Operations: The company mainly achieves income from the development of innovative and comprehensive solutions that correspond to CN -279.62 million ¥. In the segments, it causes scalp disease and in skin care products in China and Hong Kong.

Cutia Therapeutics, who navigated through a transformative phase, reported on a significant leap to sales to 279.62 million CNY compared to 137.62 million CNY last year and showed an impressive annual growth rate of 103.2%. Despite its current unprofitable with a net loss, which was dramatically reduced from 1.96 billion CNY to CNY 433.81 million, the future of the company looks promising, since it is expected to be profitable within three years, whereby the profit is forecast that the profit grows annually by 65%. This growth disease is well above the average of the market and shows the potential of Cutia to effectively use its F&E investment in a strongly competitive biotech landscape.

Sehk: 2487 profit and sales growth in May 2025

Simply wall st -growth level: ★★★★earch

Overview: Xiamen Amoytop Biotech Co., Ltd. focuses on research, development, production and the sale of recombinant protein medications in China with a market capitalization of 28.92 billion yen.

Leave a Comment